AI Terminal
Haleon PLC
Transaction in Own Shares • Mar 31, 2025
5111_pos_2025-03-31_79197ae4-00bf-4d16-b0a3-dc45f92279cc.html
Transaction in Own Shares
Open in ViewerOpens in native device viewer
National Storage Mechanism | Additional information 
RNS Number : 7901C
Haleon PLC
31 March 2025
Haleon plc: Transaction in own shares
31 March 2025: Haleon plc (the "Company" or "Haleon") today announces the purchase of the following number of ordinary shares of £0.01 each in the Company (the "Shares") for cancellation under its share buyback programme announced on 28 March 2025 (the "Buyback Programme") .
| Date of purchase: | 28 March 2025 |
| Number of Shares purchased: | 581,885 |
| Highest price paid per Share (p): | 391.20 |
| Lowest price paid per Share (p): | 384.00 |
| Volume weighted average price paid per Share (p): | 388.51 |
Following the settlement of the above, the Company's registered share capital is 9,038,988,190 ordinary shares of £0.01 each, of which 4,080,205 are held as treasury shares. Therefore, the number of ordinary shares with voting rights is 9,034,907,985 and this figure may be used by shareholders to determine if they are required to notify their interest, or a change to their interest, in Haleon under the FCA's Disclosure Guidance and Transparency Rules.
In accordance with Article 5(1)(b) of Regulation (EU) No 596/2014 as it applies in the UK (the Market Abuse Regulation), a full breakdown of the individual trades is available at the link below:
http://www.rns-pdf.londonstockexchange.com/rns/7901C_1-2025-3-28.pdf
This announcement does not constitute, or form part of, an offer or any solicitation of an offer for securities in any jurisdiction.
This announcement and individual trade breakdown will also be available on the Company's website at: www.haleon.com/investors .
| Enquiries | |||
| Investors | Media | ||
| Jo Russell | + 44 7787 392441 | Zo ë Bird | +44 7736 746167 |
| Rakesh Patel | +44 7552 484646 | Victoria Durman | +44 7894 505730 |
| Emma White | +44 7823 523562 | ||
| Email: [email protected] | Email: [email protected] |
About Haleon
Haleon (LSE / NYSE: HLN) is a global leader in consumer health, with a purpose to deliver better everyday health with humanity. Haleon's product portfolio spans five major categories - Oral Health, Pain Relief, Respiratory Health, Digestive Health and Other, and Vitamins, Minerals and Supplements (VMS). Its long-standing brands - such as Advil, Sensodyne, Panadol, Voltaren, Theraflu, Otrivin, Polident, parodontax and Centrum - are built on trusted science, innovation and deep human understanding.
For more information, please visit www.haleon.com .
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
POSKVLFLEXLLBBD